SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
In this analysis, researchers aimed to quantify and bring attention to the time burden experienced by cancer patients enrolled in phase 2 clinical trials.
This article is part of a Health Affairs Forefront series on “The Future of Sickle Cell Disease Research and Care” with support from the American Society of Hematology. The articles in the series are ...
Faculty in this hub lead the design, coordination, and analysis of clinical trials for cancer treatment, survivorship, vaccine efficacy, infectious disease prevention and treatment, and cancer ...
Modern health research has entered a phase of rapid transformation where scientific knowledge is not only expanding but ...
5d
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results